Coherus Sells Last Biosimilar Udenyca to Intas for $558M, Focuses on Cancer Drugs

Coherus BioSciences has finalized a significant agreement to sell its biosimilar product, Udenyca, to Intas Pharmaceuticals for a sum of up to $558.4 million. This transaction includes an upfront payment of $483.4 million, with the potential for an additional $75 million contingent upon sales milestones, and is expected to close by the end of the first quarter of 2025[1][2]. Intas will take over the U.S. rights to Udenyca and its various formats, assuming full responsibility for the product's franchise. The proceeds from this sale will be used by Coherus to repay $230 million in debt and fulfill $49 million in royalty obligations, as part of the company's broader strategy to pivot towards its immuno-oncology portfolio focusing on cancer therapies like Loqtorzi[2]. This move marks Coherus' exit from the biosimilar market, following earlier sales of its Lucentis biosimilar Cimerli and Humira biosimilar Yusimry, as the company sharpens its focus on the development of innovative cancer treatments[1].